IXHL Stock Risk & Deep Value Analysis
Incannex Healthcare Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
The Bottom Line on IXHL
We analyzed Incannex Healthcare Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IXHL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈IXHL Performance Overview3yr weekly
Unlock IXHL Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
IXHL Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Incannex Healthcare Inc (IXHL)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap Category
small
Market Cap
$146.45M
IXHL Deep Value Analysis
IXHL Red Flags & Warning Signs
Premium- ⚠
Negative or inconclusive results from IHL-42X Phase 2 trial
- ⚠
Failure to secure adequate funding for ongoing clinical development
- ⚠
Increased regulatory hurdles for cannabinoid or psychedelic treatments
- ⚠
Competitive advancements from larger pharmaceutical companies
Unlock IXHL Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
IXHL Financial Health Metrics
Market Cap
$146.45M
IXHL Competitive Moat Analysis
PremiumMoat Rating
None
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is currently nascent and entirely dependent on successful clinical trial outcomes leading to regulatory approval and robust patent protection. Should these materialize, a narrow moat could form due to proprietary drug formulations and unique indications. However, without successful trials, the moat is non-existent.
IXHL Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
IXHL Catalysts & Growth Drivers
Near-Term (0-6 months)
- •IHL-42X Phase 2 clinical trial readouts for Obstructive Sleep Apnea (OSA) (Timing expected within next 0-6 months)
- •Potential capital raise or strategic financing announcements
- •Updates on other pipeline candidates (e.g., IHL-675A for TBI/Concussion)
Medium-Term (6-18 months)
- •Initiation of IHL-42X Phase 3 trials (contingent on positive Phase 2 results)
- •Potential strategic partnership or licensing deal for IHL-42X
- •Advancement of other drug candidates into later-stage clinical trials
Long-Term (18+ months)
- •Commercialization of IHL-42X or other approved compounds
- •Disruption of existing OSA or TBI treatment markets
- •Establishment of Incannex as a leader in cannabinoid/psychedelic therapeutics
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
IXHL Bull Case: What Could Go Right
- ✓
Positive results from IHL-42X Phase 2 clinical trial (primary outcome measures and safety profile)
- ✓
Successful securing of non-dilutive financing or significant strategic partnerships
- ✓
Clear regulatory pathway guidance from health authorities (e.g., FDA, EMA)
- ✓
Cash burn rate and projected cash runway (monitor for further dilution risks)
Bull Case Analysis
See what could go right with Premium
Never miss a move on IXHL
Create a free account to set price alerts and get notified on Telegram when IXHL hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Incannex Healthcare Inc (IXHL)?
As of March 21, 2026, Incannex Healthcare Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Incannex Healthcare Inc?
Incannex Healthcare Inc's market capitalization is approximately $146.5M. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Incannex Healthcare Inc use?
IXHL is the ticker symbol for Incannex Healthcare Inc. The company trades on the NCM.
What is the risk level for IXHL stock?
Our analysis rates Incannex Healthcare Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the IXHL DVR analysis updated?
Our AI-powered analysis of Incannex Healthcare Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.